Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Dr. C. (Cor) van den Bos

Pediatric oncologist
Dr. C. (Cor) van den Bos

As a pediatric oncologist at the Princess Máxima Center, I am involved with acute care on the nursing wards and outpatient treatment for all patients with blood cancers. I treat children with Langerhans Cell Histiocytosis (LCH) and Acute Lymphatic Leukemia (ALL). As the chairperson for the Langerhans Cell Histiocytosis protocol committee, I try to improve the treatment of children with LCH further in collaboration with (inter-) national colleagues. I do this as a researcher in clinical and pre-clinical studies. I am also the Chef de Clinique for hematology-oncology outpatient treatment.

Specialisme / subspecialisme: Hemato-oncologie, speciale aandacht voor Langerhans Cel Histiocytose (LCH) en acute lymfatische leukemie (ALL)

Kennis en ervaring

Werkervaring

  • 1987 – 1988: dienstplichtig arts, Seedorf, Duitsland
  • 1988 – 1992: promotie onderzoek Afdeling Radiobiologie Erasmus Universiteit Rotterdam / Radiobiologisch Instituut TNO Rijswijk
  • 1992 – 1997: opleiding tot kinderarts, Catharina Ziekenhuis, Eindhoven en Wilhelmina Kinderziekenhuis, Utrecht
  • 1997 – 1999: Klinisch Fellowship KWF Kankerbestrijding / opleiding tot kinderarts-oncoloog: Wilhelmina Kinderziekenhuis, Utrecht, Great Ormond Street Hospital, Londen, en Emma Kinderziekenhuis / AMC, Amsterdam
  • 1999 – 2018: Staflid, afdeling kinderoncologie Emma Kinderziekenhuis / Academisch Medisch Centrum, Amsterdam
  • 2018: staflid hemato-oncologie Prinses Máxima Centrum


Wetenschappelijk

  • Betrokken bij nationale en internationale studies op het gebied van Langerhans Cel Histiocytose.
  • Hoofdonderzoeker LCH-IV studie van de Histiocyte Society, daardoor lid van de LCH-IV Study Management Group.
  • Lid en voorzitter LCH Steering Committee van de Histiocyte Society (tot 2019)
  • Lid Scientific Programme Advisory Committee (SPAC) van de SIOP (tot 2019)

 
Mijn publicaties in pubmed zijn te zien via deze link.

5 geselecteerde publicaties

  • Ilse Schuitema, Sabine Deprez, Wim van Hecke, Marita Daams, Anne Uyttebroeck, Stefan Sunaert, Frederik Barkhof, Eline van Dulmen-den Broeder, Helena J. van der Pal, Cor van den Bos, Anjo J.P. Veerman, and Leo M.J. de Sonneville
    Accelerated Aging, Decreased White Matter Integrity and Associated Neuropsychological Dysfunction 25 Years after Pediatric Lymphoid Malignancies
    J Clin Oncol (2013) 31: 3378-3388
  • David Nelson, Willemijn T Quispel, Gayane Badalian-Very, Astrid GS van Halteren, Cor van den Bos, Judith V.M.G. Bovée, Sara Tian, Paul Van Hummelen, Matthew Ducar, Laura MacConaill, R Maarten Egeler, and Barrett J. Rollins Somatic Activating ARAF mutations in Langerhans cell histiocytosis Blood (2014) 123: 3152-3155
  • David S. Nelson, Astrid van Halteren, Willemijn Quispel, Cor van den Bos, Judith V.M.G. Bovée, Bhumi Patel, Gayane Badalian-Very, Paul van Hummelen, Matthew Ducar, Laura E. MacConail, R. Maarten Egeler, Barrett J. Rollins MAP2K1 and MAP3K1 mutations in Langerhans Cell Histiocytosis Genes Chromosomes & Cancer (2015) 54: 362-368
  • Deepak Chellapandian, Furqan Shaikh, Cor van den Bos, Gino Somers, Itziar Astigarraga, Rima Jubran, Barbara Degar, Anne-Sophie Carret, Karen Mandel, Mark Belletrutti, David Dix, Johannes Visser, Nour Abuhadra, Tiffany Chang, Barret Rollins, James Whitlock ,Sheila Weitzman, Oussama Abla Management and outcome of patients with Langerhans cell histiocytosis and single-bone CNS-risk lesions; a multicenter retrospective study Ped Blood Cancer (2015) 62:2162-2166
  •  Jean Donadieu, Frederic Bernard, Max van Noesel, Mohamed Barkaoui, Odile Bardet, Rosella Mura, Maurizio Arico, Christophe Piguet, Virginie Gandemer, Corinne Armari Alla, Niels Clausen, Eric Jeziorski, Anne Lambilliote, Sheila Weitzman, Jan Inge Henter, and Cor van den Bos Cladribine and Cytarabine in Refractory Multisystem Langerhans Cell Histiocytosis (LCH): Results of an International Phase II Study Blood (2015) 126: 1415-1423

Contactgegevens
Telefoon 088-9729508